Form 4: Teladoc Health Director Mark Smith Granted Restricted Stock Units

Teladoc Health, Inc. Director Mark Douglas Smith was granted 28,986 restricted stock units (RSUs) as part of his compensation, which are set to vest by May 2026.

Summary

• Mark Douglas Smith, a Director of Teladoc Health, Inc. (TDOC), acquired 28,986 Restricted Stock Units (RSUs) on May 22, 2025.
• Each RSU represents a contingent right to receive one share of TDOC common stock.
• The RSUs will vest in full on the earlier of May 22, 2026, or the day immediately preceding the issuer's 2026 annual meeting of stockholders.
• Vested shares will be delivered to Mr. Smith within 90 days following 30 days after his separation of service, immediately prior to, on or within 30 days following a Change of Control, or upon his death.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns director interests with shareholders, but it is largely neutral as it represents a routine and expected compensation event for a public company director.

Positives

• The grant of Restricted Stock Units aligns the interests of Director Mark Douglas Smith with those of Teladoc Health shareholders, as the value of his compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for non-employee directors, indicating a routine and expected compensation structure.

Negatives

• The vesting of these RSUs will result in a minor dilution of existing shareholder equity when the shares are eventually delivered, though this is a common aspect of equity compensation plans.

Future Outlook

The Restricted Stock Units are scheduled to vest by May 22, 2026, or earlier, leading to the future delivery of Teladoc Health common stock to the reporting person under specified conditions.

Industry Context

The granting of Restricted Stock Units to non-employee directors is a common practice across publicly traded companies, particularly in the healthcare technology sector, to attract and retain qualified board members and align their incentives with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of compensation for non-employee directors is a widely adopted practice across various industries, including healthcare technology, aligning with global benchmarks for corporate governance and executive/director remuneration.
• While specific comparable companies or projects are not detailed in this Form 4, similar RSU grants are observed at companies like Amwell (AMWL), Livongo (acquired by Teladoc), and other digital health providers, where equity compensation forms a significant part of director pay packages.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Director Mark Douglas Smith constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, but also entails minor future dilution upon vesting and delivery of shares.
• Director (Mark Douglas Smith): Receives equity compensation for board service, providing a direct stake in the company's future performance.

Next Steps

• The Restricted Stock Units will vest on the earlier of May 22, 2026, or the day preceding the 2026 annual meeting of stockholders.
• Vested shares will be delivered to Mark Douglas Smith upon specific triggering events, including separation of service, a Change of Control, or death.

Key Dates

Keywords

Teladoc Health, TDOC, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation